MED Company Profile and Key Details

MED has shown mixed momentum, losing -0.26% over the past week and -9.75% over the past quarter, though year-to-date performance is up 9.18%. Short-term trend indicators are bullishly aligned (SMA20 -4.41%, SMA50 -7.02%, SMA200 -17.93%). The stock’s 14-day RSI is 37.36 (weak momentum), while the ATR of 0.44 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -32.54% below its high and over 3.27% above its low. Average 10-day trading volume of 194.85 thousand shares is below the 3-month average of 240.30 thousand, indicating normal recent market interest.

The latest quarter delivered EPS of -$0.19. The next quarter is forecast at -$0.52. Next year's EPS is expected at -$43.21. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $15.00. The high target offers 14.59% upside. The low target suggests 14.59% downside. The mean target is $15.00. This offers 14.59% upside. Medifast, Inc. earnings surprise history is a mixed track record. The quarter that ended May 04, 2026, missed forecasts by -65.45%. The prior quarter beat by -27.63%. Over the last six quarters, Apple has recorded several small beats. These include -162.5% in February 18, 2025.

Medifast, Inc. has 10.99 million shares outstanding. The public float is 9.15 million shares, elevated short interest at 21.41% of float. This equals 2.29 million shares. The short ratio is 11.35 days. Institutional investors hold 81.28% of the float. Insiders own 3.86%. SCHLACKMAN SCOTT holds 30.55 thousand shares, Chard Daniel R has 17.68 thousand shares and Hoer Michael A. has 8.38 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Medifast, Inc. last paid a dividend of 0 per share, this equals a trailing yield of roughly 17.57%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $501.46. This means the shares are trading below this model’s fair value.

Medifast, Inc. (NYSE:MED) closed at $12.72 USD, losing -$0.37 (-2.83%) from the previous close of $13.09. The stock is currently mid-range between its 52-week high and low $9.22 and $15.46. With a market capitalization of about $141.43 million, Medifast, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.57). Key stats such as the average daily volume over the past year has been around 235.09 thousand shares, volume is running light vs its 52-week average. Headquartered in Baltimore, MD, Medifast, Inc. operates in the Consumer Cyclical sector and the Personal Products & Services industry. Led by CEO Daniel R. Chard, the company employs approximately 504 people and listed since December 30, 1993. Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific.

Medifast, Inc. trades at a P/E ratio of -6.95, slightly below the S&P 500 average, with a price-to-sales ratio of 0.41 and a price-to-book ratio of 0.7 suggesting the stock is closer to book value. The P/FCF stands at -95.62, also below market averages.

Our AI price prediction model suggests that Medifast, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.11%, with price expected at $13.89 by June 09, 2026, within a range of $13.36 to $14.41 3-Month Outlook: Projected rise of 52.1%, reaching $19.91 by August 24, 2026, with a range of $19.32 to $20.47. 1-Year Outlook: Projected gain of 1.76%, with price at $13.32 by May 26, 2027, within a range of $5.84 to $12.93.

Medifast, Inc. (NYSE:MED) shares are flat 9.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Medifast, Inc. trading at a premium to the broader market with a P/E of -6.95. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $79.54, suggesting 507.64% upside. Our AI forecast model points to short-term strength (6.11% over two weeks), a medium-term rise (52.1% over three months), and a longer-term gain (1.76% over one year), with expected trading ranges indicating moderate volatility.